The following table summarizes the results of the Company’s allocation:
| (in thousands) | ||||
|
Ucyclyd’s retention option amount |
$ | 32,000 | ||
|
Amount due to Ucyclyd for BUPHENYL product rights |
(19,000 | ) | ||
|
Amount due to Ucyclyd for inventory |
(2,038 | ) | ||
|
|
|
|||
|
Net payment received from Ucyclyd |
10,962 | |||
|
Option to purchase the rights to BUPHENYL and AMMONUL |
(283 | ) | ||
|
Fair value of BUPHENYL |
20,400 | |||
|
|
|
|||
|
Gain from settlement of retention option |
$ | 31,079 | ||
|
|
|
|||